Eli Lilly Unveils Higher Single-Dose Zepbound Vials for $499 a Month
Portfolio Pulse from
Eli Lilly has introduced a new, more affordable single-dose vial of its weight-loss drug Zepbound, priced at $499 per month for self-paying patients. Additionally, the company has reduced the prices of two existing doses.
February 25, 2025 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's introduction of a cheaper single-dose vial of Zepbound and price cuts on existing doses could boost sales and market share in the weight-loss drug market.
The introduction of a more affordable option for Zepbound is likely to attract more self-paying patients, potentially increasing sales. Price reductions on existing doses may also make the product more competitive in the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100